Table 1.
Demographics characteristics of patients by steroids timing (n=247)
| Patient’s characteristics | Steroids <2 months | Steroids ≥2 months | P value |
| Median age (IQR), overall: 69 | 67 (13) years | 71 (15) | 0.0048 |
| Gender | |||
| Male | 87 (52.73) | 78 (47.27) | 0.8232 |
| Female | 42 (51.22) | 40 (48.78) | |
| Race | |||
| Black | 28 (53.85) | 24 (46.15) | 0.04* |
| White | 99 (54.10) | 84 (45.90) | |
| Others | 2 (16.67) | 10 (83.33) | |
| Smoking | |||
| Never/light smoker | 59 (57.28) | 44 (42.72) | 0.1619 |
| Heavy smoker | 69 (48.25) | 74 (51.75) | |
| ECOG grade | |||
| Grade 0 | 45 (51.44) | 43 (48.86) | 0.3242 |
| Grade 1 | 50 (47.17) | 56 (52.83) | |
| Grade 2 | 28 (63.63) | 16 (36.36) | |
| Grade 3 | 3 (50.00) | 3 (50.00) | |
| BMI | |||
| Underweight | 15 (51.72) | 14 (48.28) | 0.4375 |
| Normal | 56 (26.67) | 41 (42.27) | |
| Overweight | 30 (51.72) | 28 (48.28) | |
| Obese | 28 (21.71) | 35 (55.56) | |
| Brain metastases | |||
| Yes | 29 (64.44) | 16 (35.56) | 0.0696 |
| No | 100 (49.50) | 102 (41.30) | |
| Cancer subtypes | |||
| NSCLC | 45 (45.92) | 53 (54.08) | 0.0395* |
| RCC | 22 (51.16) | 21 (48.84) | |
| Melanoma | 19 (63.33) | 11 (36.67) | |
| Urothelial | 8 (57.14) | 6 (42.86) | |
| HCC | 4 (40.00) | 6 (60.00) | |
| Small cell | 15 (88.24) | 2 (11.76) | |
| Other | 16 (45.71) | 19 (54.29) | |
| Drug | |||
| Nivolumab | 94 (55.95) | 74 (44.05) | 0.0531 |
| Pembrolizumab | 24 (39.34) | 37 (60.66) | |
| Atezolizumab | 9 (69.23) | 4 (30.77) | |
| Durvalumab | 1 (25.00) | 3 (75.00) | |
| Ipilimumab | |||
| Ipilimumab received | 96 (49.23) | 99 (50.77) | 0.0348* |
| Ipilimumab not received | 30 (66.67) | 15 (33.33) |
*Statistically significant at 0.05.
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; HCC, Hepatocellular Carcinoma; NSCLC, non-small cell lung cancer; RCC, Renal Cell Carcinoma.